基于大麻的纤维肌痛药物配方的比较:一个队列研究
Surya Sridharan1, Simon Erridge1,2, Carl Holvey2
1Medical Cannabis Research Group, Imperial College London, London, UK.
Journal of pain & palliative care pharmacotherapy
|October 17, 2024
概括
这项研究发现,大麻制药 (CBMP) 改善了纤维肌痛患者的症状. 在各种结果中都出现了改善,不良事件在新用户中更为常见.
科学领域:
- 医学研究 医学研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 纤维肌痛是一种慢性疾病,具有广泛的疼痛特征.
- 基于大麻的药物 (CBMP) 越来越多地用于慢性疼痛管理.
- 在英国,关于纤维肌痛的同质CBMPs的数据有限.
研究的目的:
- 评估纤维肌痛患者的结果,使用来自英国医用大麻注册表的特定CBMP.
- 评估患者报告结果和不良事件的变化.
主要方法:
- 一项对148名纤维肌痛患者的队列研究规定CBMPs (油,干花或两者兼而有之).
- 主要结局测量了经过验证的患者报告的结局措施在1,3,6和12个月的变化.
- 二级结果包括对不良事件的分析.
主要成果:
- 在所有随访点 (p < 0.050) 观察到焦虑,睡眠质量,纤维肌痛症状严重程度和生活质量 (EQ-5D-5L) 的显著改善.
- 不同的CBMP配方之间没有发现结果的显著差异.
- 24.32%的参与者报告了不良事件,在未使用大麻的患者中更为频繁.
结论:
- 同质的CBMP显示出改善纤维肌痛症状的积极信号.
- 副作用是可以管理的,并且在新使用大麻的人群中更为普遍.
- 这些发现支持对特定CBMP品种进行随机对照试验的进一步调查.
相关概念视频
Bioequivalence: Overview
932
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
932
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.2K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.2K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
237
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
237
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
203
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
203
Analgesia and Pain Management
540
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
540
Drug Dosage Regimen: Overview
3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K


